Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

• Published in: Haematologica (Roma) Vol. 106; no. 10; pp. 2667 - 2672
• Main Authors: Strati, Paolo, Varma, Ankur, Adkins, Sherry, Nastoupil, Loretta J, Westin, Jason, Hagemeister, Fredrick B, Fowler, Nathan H, Lee, Hun J, Fayad, Luis E, Samaniego, Felipe, Ahmed, Sairah, Chen, Yiming, Horowitz, Sandra, Arafat, Sara, Johncy, Swapna, Kebriaei, Partow, Mulanovich, Victor Eduardo, Ariza Heredia, Ella, Neelapu, Sattva S
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.10.2021; Ferrata Storti Foundation
• Subjects: Antigens, CD19; Biological Products; Humans; Immune Reconstitution; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse - drug therapy; Neutropenia

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene cilo...